Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018

  • ID: 4457543
  • Report
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CytoTools AG
  • Daval International Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • GangaGen Inc
  • MediWound Ltd
  • MORE
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 5, 1, 4 and 2 respectively.

Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CytoTools AG
  • Daval International Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • GangaGen Inc
  • MediWound Ltd
  • MORE
Introduction

Venous Leg Ulcers (Crural ulcer) - Overview

Venous Leg Ulcers (Crural ulcer) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development

CardioVascular BioTherapeutics Inc

CytoTools AG

Daval International Ltd

Factor Therapeutics Ltd

FirstString Research Inc

GangaGen Inc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma

Stratatech Corp

Venous Leg Ulcers (Crural ulcer) - Drug Profiles

Aimspro - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUP-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVBT-141B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diperoxochloric acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LL-37 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-42909 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Venous Leg Ulcers (Crural ulcer) - Dormant Projects

Venous Leg Ulcers (Crural ulcer) - Discontinued Products

Venous Leg Ulcers (Crural ulcer) - Product Development Milestones

Featured News & Press Releases

Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Nov 02, 2017: VF001002 Clinical Trial Update: Strong performance in October driven by new sites

Oct 31, 2017: Promore Pharma Signs Agreement with CRO PCG Clinical Services

Sep 21, 2017: Promore Pharma Signs Manufacturing Agreement with APL

Sep 12, 2017: Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

Sep 01, 2017: MediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study

May 22, 2017: Factor Therapeutics Appoints Dr. Rosalind Wilson as CEO

Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update

Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board

May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial

Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update

Jun 29, 2015: CytoTools announces positive intermediate results for the European ulcus cruris trial - seamless transition into an approval-relevant phase III trial with less number of patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by Daval International Ltd, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by Factor Therapeutics Ltd, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research Inc, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by GangaGen Inc, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by Promore Pharma, H1

Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corp, H1

Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1

Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1

List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CardioVascular BioTherapeutics Inc
  • CytoTools AG
  • Daval International Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • GangaGen Inc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • Promore Pharma
  • Stratatech Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll